Bristol-Myers Squibb Co.’s (BMY) cancer drug Opdivo has demonstrated long term survival benefit in patients with previously treated non-squamous non-small cell lung cancer – with an estimated 39% of patients alive at 18 months compared to 23% for Docetaxel, based on a minimum follow-up of 17.1 months, in a phase III trial dubbed CheckMate -057.